Relispray Antifungal Liquid Aerosol, Spray
NDC 46063-810
Product Information
Relispray Antifungal Liquid (tolnaftate) is a OTC MONOGRAPH DRUG-approved product labeled by Midas-care Pharmaceuticals Pvt. Ltd.. Tolnaftate is used to treat skin infections such as athlete's foot, jock itch, and ringworm. It is supplied as a aerosol, spray for topical administration. This product entry covers the primary NDC 46063-810 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 46063-810?
What are the uses of this product?
What are Active Ingredients of this product?
- TOLNAFTATE .01 g/g - A synthetic antifungal agent.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TOLNAFTATE (UNII: 06KB629TKV)
- TOLNAFTATE (UNII: 06KB629TKV) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)
- FRAGRANCE CLEAN ORC0600327 (UNII: 329LCV5BTF)
- POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
- LIQUEFIED PETROLEUM GAS (UNII: 5K616HU99V)
- ALCOHOL (UNII: 3K9958V90M)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 313421 - tolnaftate 1 % Topical Spray
- RxCUI: 313421 - tolnaftate 10 MG/ML Topical Spray
* Please review the full disclaimer at the bottom of this page.
Patient Education
Tolnaftate
Tolnaftate stops the growth of fungi that cause skin infections, including athlete's foot, jock itch, and ringworm. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
[Learn More]
* Please review the full disclaimer at the bottom of this page.